Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]
In development
Reference number: GID-TA10900
Expected publication date: TBC
The timelines for this appraisal have been updated due to changes in the regulatory timelines for this technology.
NICE will be reissuing the Invitation to Participate (ITP) in mid-August 2022 to ensure that all consultees and commentators participating in the appraisal submit evidence or comments in accordance with the NICE health technology evaluations: the manual (2022) and we will confirm the new timelines at this stage.